Eris Lifesciences Limited

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on August 31, 2026, where the Board of Directors approved the re-appointment of Mr. Sujesh Vasudevan as Independent Director of the Company for another period of 5 years, commencing from July 25, 2027, and convened the 20th Annual General Meeting of the Members of the Company on Friday, September 25, 2026.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about a scheduled meeting with institutional investors on August 27, 2026, to discuss publicly available documents.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about the schedule of an analyst/institutional investor meet/conference call on August 17, 2026, where the management will discuss publicly available documents and no unpublished price sensitive information will be disclosed.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about the schedule of an analyst/institutional investor meet/conference call on August 14, 2026, where the company's management will discuss publicly available documents and no unpublished price-sensitive information will be disclosed.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about a Loan Agreement with Axis Bank Limited for a working capital term loan of ₹64,40,00,000 to meet other short-term liabilities.

Eris Lifesciences Limited

Eris Lifesciences Limited has made available the transcript of its Analyst and Investor call held after the announcement of financial results for the quarter ended June 30, 2026. The transcript is available on the company's website at https://eris.co.in/financials/

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting on August 4, 2026, to be attended by the company's management.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange regarding the allotment of 4816 shares under the ESOP-2017 Scheme, increasing the company's paid-up share capital from Rs. 13,85,78,489 to Rs. 13,85,83,305.

Eris Lifesciences Limited

Eris Lifesciences Limited has made available the recording of its earnings conference call for the quarter ended June 30, 2026, on its website.

Eris Lifesciences Limited

Eris Lifesciences Limited has released its Q1 FY27 financial highlights, showing a 14.2% YoY revenue growth and 14.5% YoY consolidated PAT growth. The company's Domestic Branded Formulations (DBF) segment reported a 14.2% organic growth, with 7 out of 10 therapies in its portfolio clocking double-digit growth rates. The company has established an early leadership in the GLP-1 (Semaglutide) market and has a strong pipeline of 5 insulin products set to launch starting FY28.

Eris Lifesciences Limited

Eris Lifesciences Limited has submitted its financial results for the period ended June 30, 2026, and has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about the schedule of an analyst and investor call to discuss the unaudited financial results for the quarter ended June 30, 2026. The call is scheduled for July 29, 2026, at 4:30 PM IST.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the securities received for dematerialisation during the quarter ended 30th June 2026.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed for all Designated Persons and their immediate relatives from July 01, 2026, and will remain closed till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ending on June 30, 2026.

Eris Lifesciences Limited

Eris Lifesciences Limited has informed the Exchange regarding the allotment of 11,233 equity shares pursuant to the exercise of options under the ESOP Scheme, increasing the paid-up share capital from ₹13,85,67,256 to ₹13,85,78,489.

Eris Lifesciences Limited

Eris Lifesciences Limited has released a corporate presentation highlighting its robust business performance and strategic growth. The company has secured a position among the Top-20 Indian pharmas within 20 years, with 80% of revenue from super-specialty segments. It holds leading market shares in anti-diabetes therapy and insulins, and has seen a strong start with its Gx Semaglutide brand. The presentation also emphasizes successful leveraged acquisitions to enter high-value therapies and significant growth potential in its international business.